Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Notified -...

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Notified -...

Boehringer Ingelheim expands cancer research at its Vienna site

Boehringer Ingelheim expands cancer research at its Vienna site

...

menu
menu